Iloprost

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages) This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Iloprost" – news · newspapers · books · scholar · JSTOR (December 2010) (Learn how and when to remove this message) This article contains close paraphrasing of non-free copyrighted sources. Relevant discussion may be found on the talk page. Please help Wikipedia by rewriting this article with your own words. (February 2024) (Learn how and when to remove this message) This article may be in need of reorganization to comply with Wikipedia's layout guidelines. Please help by editing the article to make improvements to the overall structure. (February 2024) (Learn how and when to remove this message) This article may need to be rewritten to comply with Wikipedia's quality standards. You can help. The talk page may contain suggestions. (February 2024) (Learn how and when to remove this message)

Iloprost

Clinical data
Trade names	Ventavis, Ilomedine, Aurlumyn
AHFS/Drugs.com	Monograph
MedlinePlus	a612032
License data	US DailyMed: Iloprost
Routes of administration	Inhalation, intravenous
ATC code	B01AC11 (WHO)
Legal status
Legal status	US: ℞-only[1][2] EU: Rx-only[3] In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	Not determined[1]
Protein binding	60%[1]
Metabolism	Via β-oxidation to inactive tetranor-iloprost[1]
Elimination half-life	20–30 minutes[1]
Excretion	Kidney (68%) and fecal (12%)[1]
Identifiers
IUPAC name 5-{(E)-(1S,5S,6R,7R)-7-hydroxy-6[(E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl]-bicyclo[3.3.0]octan-3-ylidene}pentanoic acid
CAS Number	78919-13-8 Y 73873-87-7
PubChem CID	5311181
DrugBank	DB01088 Y
ChemSpider	4470703 N
UNII	JED5K35YGL
KEGG	D02721 Y
ChEMBL	ChEMBL236025 Y
CompTox Dashboard (EPA)	DTXSID2041046
ECHA InfoCard	100.163.887
Chemical and physical data
Formula	C22H32O4
Molar mass	360.494 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC#CCC(C)[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/C2)O)O
InChI InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1 N Key:HIFJCPQKFCZDDL-ACWOEMLNSA-N N
NY (what is this?)  (verify)

Iloprost, sold under the brand name Ventavis among others, is a medication used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon, frostbite, and other conditions in which the blood vessels are constricted and blood cannot flow to the tissues.^[4] Iloprost is a prostacyclin mimetic.^[1]

For pulmonary arterial hypertension, iloprost is given via inhalation. Iloprost works by opening (dilating) the blood vessels to allow the blood to flow through them. It was developed by the pharmaceutical company Schering AG and is marketed by Bayer Schering Pharma AG in the European Union and by Actelion Pharmaceuticals in the US.